Search
Pharonova Therapeutics has recently made an announcement regarding the successful completion of its angel-round funding, raising close to 100 million yuan. This financing round was co-led by China Growth Capital and Boyuan Capital, with additional support from Mint Angel Fund and other investors. The capital raised will be strategically allocated to three key areas: firstly, to expedite the development of preclinical candidate molecules for the STAT6 project and facilitate the Investigational New Drug (IND) application process; secondly, to comprehensively drive forward the IND application for PPI-101, a core pipeline degrader; and thirdly, to accelerate the refinement and enhancement of the AI drug R&D platform, which is centered around protein-protein interactions (PPI).
-
C114 Communication Network -
Communication Home
